Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems

Advances in artificial intelligence (AI) and synthetic biology are transforming biological research and biotechnology. These fields are for the first time enabling the design and development of human and bacterial cells that can serve as "living" drug delivery vehicles that perform sustained release of therapeutic cargo with spatiotemporal control. In recent years, human and bacterial cells have been engineered to deliver peptides, proteins, and biologics for treating a wide range of human diseases using synthetic biology approaches. To engineer effective living drug delivery systems, detailed knowledge is required about how to design receptors that can specifically sense the tissues targeted for drug delivery, signaling networks that can process signals from these receptors, and gene circuits that can control therapeutic cargo production and release. However, elucidating such receptors, signal processing and gene regulatory elements, and gene circuit compositions by traditional design-build-test-learn approaches is difficult and low throughput. Here we review how advances in AI and synthetic biology are meeting these challenges. We describe examples of how human cells and bacteria are engineered to become living drug delivery vehicles. We discuss how AI and synthetic biology approaches are being applied to discover the sequence-to-function design principles for engineering synthetic receptors, signaling proteins, and gene regulatory elements and the composition-to-function design principles for engineering synthetic gene circuits. We share an outlook on opportunities for AI and synthetic biology to synergize for creating next-generation living drug delivery systems.

Authors

Institutions

Publication Details

Journal
Advanced Drug Delivery Reviews
Published
2026-04-27
DOI
https://doi.org/10.1016/j.addr.2026.115883
Primary Topic
Molecular Communication and Nanonetworks
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems

Jason H. Yang, Caleb J. Bashor
Advanced Drug Delivery Reviews
Molecular Communication and Nanonetworks
article

Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems

Jason H. Yang, Caleb J. Bashor
article en

Abstract

Advances in artificial intelligence (AI) and synthetic biology are transforming biological research and biotechnology. These fields are for the first time enabling the design and development of human and bacterial cells that can serve as "living" drug delivery vehicles that perform sustained release of therapeutic cargo with spatiotemporal control. In recent years, human and bacterial cells have been engineered to deliver peptides, proteins, and biologics for treating a wide range of human diseases using synthetic biology approaches. To engineer effective living drug delivery systems, detailed knowledge is required about how to design receptors that can specifically sense the tissues targeted for drug delivery, signaling networks that can process signals from these receptors, and gene circuits that can control therapeutic cargo production and release. However, elucidating such receptors, signal processing and gene regulatory elements, and gene circuit compositions by traditional design-build-test-learn approaches is difficult and low throughput. Here we review how advances in AI and synthetic biology are meeting these challenges. We describe examples of how human cells and bacteria are engineered to become living drug delivery vehicles. We discuss how AI and synthetic biology approaches are being applied to discover the sequence-to-function design principles for engineering synthetic receptors, signaling proteins, and gene regulatory elements and the composition-to-function design principles for engineering synthetic gene circuits. We share an outlook on opportunities for AI and synthetic biology to synergize for creating next-generation living drug delivery systems.

Advanced Drug Delivery ReviewsVol. 235
Rutgers, The State University of New Jersey (US), Rice University (US)
Agilent Technologies, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Rutgers, The State University of New Jersey, Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation, Office of Naval Research, National Institute of Biomedical Imaging and Bioengineering
Openalex Percentile: Top 19%
Molecular Communication and Nanonetworks
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.